Multiple Sclerosis Symptoms and Spasticity Management: New Data

References

• Stuke K , FlacheneckerP, ZettlUKet al. Symptomatology of MS: results from the German MS Registry . J. Neurol.256 ( 11 ), 1932 – 1935 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Flachenecker P , HenzeT, ZettlUK . Spasticity in patients with multiple sclerosis – clinical characteristics, treatment and quality of life . Acta Neurol. Scand.129 ( 3 ), 154 – 162 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rizzo MA , HadjimichaelOC, PreiningerovaJ, VollmerTL . Prevalence and treatment of spasticity reported by multiple sclerosis patients . Mult. Scler.10 ( 5 ), 589 – 595 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Kister I , BaconTE, ChamotEet al. Natural history of multiple sclerosis symptoms . Int. J. MS Care15 ( 3 ), 146 – 158 ( 2013 ).
   PubMedGoogle Scholar
• Kommission Leitlinien der Deutschen Gesellschaft für Neurologie. Leitlinien für Diagnostik und Therapie in der Neurologie . www.dgn.org/leitlinien .
   Google Scholar
• Halpern R , GillardP, GrahamGD, VaronSF, ZorowitzRD . Adherence associated with oral medications in the treatment of spasticity . PM R5 ( 9 ), 747 – 756 ( 2013 ).
   PubMedGoogle Scholar
• Perez J . Combined cannabinoid therapy via an oromucosal spray . Drugs Today (Barc.)42 ( 8 ), 495 – 503 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Russo E , GuyGW . A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol . Med. Hypotheses66 ( 2 ), 234 – 246 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Vermersch P . Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data . Expert Rev. Neurother.11 ( Suppl. 4 ), 15 – 19 ( 2011 ).
   PubMedGoogle Scholar
• Chong MS , WolffK, WiseK, TantonC, WinstockA, SilberE . Cannabis use in patients with multiple sclerosis . Mult. Scler.12 ( 5 ), 646 – 651 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Aldington S , HarwoodM, CoxBet al. Cannabis use and risk of lung cancer: a case-control study . Eur. Respir. J.31 ( 2 ), 280 – 286 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Wade DT , MakelaPM, HouseH, BatemanC, RobsonP . Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis . Mult. Scler.12 ( 5 ), 639 – 645 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Potter DJ . A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK . Drug Test Anal.6 ( 1–2 ), 31 – 38 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sativex Oromucosal Spray SPC . 2015 . www.medicines.org.uk/emc/history/23262 .
   Google Scholar
• Wade DT , MakelaP, RobsonP, HouseH, BatemanC . Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind: randomized: placebo-controlled study on 160 patients . Mult. Scler.10 ( 4 ), 434 – 441 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Collin C , DaviesP, MutibokoIK, RatcliffeS, Sativex Spasticity in MS Study Group . Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis . Eur. J. Neurol.14 ( 3 ), 290 – 296 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Collin C , EhlerE, WaberzinekGet al. A double-blind: randomized: placebo-controlled: parallel-group study of Sativex: in subjects with symptoms of spasticity due to multiple sclerosis . Neurol. Res.32 ( 5 ), 451 – 459 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Novotna A , MaresJ, RatcliffeSet al. A randomized: double-blind: placebo-controlled: parallel-group: enriched-design study of nabiximols* (Sativex®), as add-on therapy: in subjects with refractory spasticity caused by multiple sclerosis . Eur. J. Neurol.18 ( 9 ), 1122 – 1131 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Flachenecker P , HenzeT, ZettlUK . Nabiximols (THC/CBD oromucosal spray: Sativex®) in clinical practice – results of a multicenter: non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity . Eur. Neurol.71, 271 – 279 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C , CasanovaB, OrdásCM, VilaC, AsensioD, MassanaM . Observational safety study of THC:CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity . Clin. Exp. Pharmacol.5, 5 ( 2015 ).
   Google Scholar
• Patti F , MessinaS, SolaroCet al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity . J. Neurol. Neurosurg. Psychiatry87 ( 9 ), 944 – 951 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Etges T , KaroliaK, GrintTet al. An observational postmarketing safety registry of patients in the UK: Germany: and Switzerland who have been prescribed Sativex® (THC:CBD: nabiximols) oromucosal spray . Ther. Clin. Risk Manag.12, 1667 – 1675 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C , González-SeguraD, VilaC . Spasticity in multiple sclerosis: results of a patient survey . Int. J. Neurosci.123 ( 6 ), 404 – 408 ( 2013 ).
   Web of Science ®Google Scholar
• Coghe G , PauM, CoronaFet al. Walking improvements with nabiximols in patients with multiple sclerosis . J. Neurol.262 ( 11 ), 2472 – 2477 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Illomei G , SpinicciG, LocciE, MarrosuMG . Muscle elastography: a new imaging technique for multiple sclerosis spasticity measurement . Neurol. Sci.38 ( 3 ), 433 – 439 ( 2017 ).
   PubMed Web of Science ®Google Scholar